Puma Biotechnology | PBYI - Ebitda


Puma Biotechnology reported $729K in EBITDA for its fiscal quarter ending in June of 2024.





Ebitda Change Date
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 222.32M 76.27M Jun/2026
Daiichi Sankyo JPY 116.06B 14.46B Jun/2026
Exelixis USD 275.36M 19.96M Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
MacroGenics USD -64.54M 34.34M Jun/2026
Moderna USD -687M 571M Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026